Drug Profile

Anti-BCMA chimeric antigen receptor T cell therapy - Protheragen

Alternative Names: Anti-BCMA CAR-T cell therapy - Protheragen; BCMA - CAR-T

Latest Information Update: 28 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Protheragen
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Multiple myeloma

28 Jul 2023 No recent reports of development identified for phase-I development in Multiple-myeloma in USA (Parenteral)
22 Jun 2020 Anti-BCMA chimeric antigen receptor T cell therapy is available for licensing as of 22 Jun 2020. https://www.protheragen.com/pipeline.html
22 Jun 2020 Phase-I clinical trials in Multiple myeloma in USA (Parenteral), prior to June 2020 (Protheragen pipeline, June 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com